Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.79 |
| ▸ | S1PR3 | Q99500 | 16/20 | 0.79 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.59 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.59 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944293 | 0.92 | S1PR1 (0.71) | S1PR1S1PR3 | |
| SCHEMBL2456566 | 0.91 | S1PR1 (0.70) | S1PR1S1PR3 | |
| SCHEMBL2455984 | 0.91 | S1PR1 (0.73) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1382425 | 0.89 | S1PR1 (0.76) | S1PR1S1PR3 | |
| SCHEMBL2461792 | 0.88 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL2459070 | 0.88 | S1PR1 (0.69) | S1PR1S1PR3 | |
| SCHEMBL2454748 | 0.88 | S1PR1 (0.71) | S1PR1S1PR3 | |
| SCHEMBL2454139 | 0.87 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL13002084 | 0.87 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL2454147 | 0.86 | S1PR1 (0.72) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863475-B1 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-09-07 | — | — | EP | disclosed |
| US-7846964-B2 | Thiophene derivatives as spingosine-1-phosphate-1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20080194670-A1 | Novel Thiophene Derivatives as Spingosine-1-Phosphate-1 Receptor Agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1863475-A2 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100635-A2 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194670-A1 | Novel Thiophene Derivatives as Spingosine-1-Phosphate-1 Receptor Agonists | GRK2, GRK4, GPR174 | S1PR1 19/4885S1PR3 77/4885CACNA1G 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.